The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
Open accessPublished version of a preprint
Abstract
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2. It is conceivable that lapatinib may inhibit the function of ATP-binding cassette (ABC) transporters by binding to their ATP-binding sites. The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters. Our results showed that lapatinib significantly enhanced the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was observed in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells. Lapatinib alone, however, did not significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in sensitive and resistant cells. Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E217βG by ABCG2. Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [125I]iodoarylazidoprazosin in a concentration-dependent manner. However, lapatinib did not affect the expression of these transporters at mRNA or protein levels. Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice. Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function. These findings may be useful for cancer combinational therapy with lapatinib in the clinic. [Cancer Res 2008;68(19):7905–14]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ErbB receptor inhibitor lapatinib is an U.S. Food and Drug Administration (FDA) approved drug for the treatment of several HER2 driven cancers and has been shown to also directly inhibit the drug efflux activity of MDR1, both in cancer cells and in in vivo tumor models (36).”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [36]
In the citing paper
“lapatinib has previously been shown to be a competitive inhibitor of MDR1 both in vitro and in vivo (36)”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., Luca, A. D., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., Feo, G. D., Caponigro, F., & Salomon, D. S. (2005) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,088
The Human ATP-Binding Cassette (ABC) Transporter SuperfamilyPreprint
Dean, M. C., Rzhetsky, A., & Allikmets, R. L. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,820
P-glycoprotein: from genomics to mechanism
Ambudkar, S. V., Kimchi‐Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206948 · Cited by 1,092
Self-citationMultidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Doyle, L. A., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,056
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K., O’Neil, B. H., Marcom, P. K., Ellis, M. J., Overmoyer, B. A., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
The MRP family of drug efflux pumps
Kruh, G. D., & Belinsky, M. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206953 · Cited by 615
The Role of ABC Transporters in Drug Resistance, Metabolism and Toxicity
Glavinas, H., Krajcsi, P., Cserepes, J., & Sarkadi, B. (2004) · Current Drug Delivery · doi:10.2174/1567201043480036 · Cited by 559
Litman, T., Brangi, M., Hudson, E., Fetsch, P. A., Abati, A. D., Ross, D. D., Miyake, K., Resau, J. H., & Bates, S. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2011 · Cited by 538
Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis
Donnenberg, V. S., & Donnenberg, A. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005276905 · Cited by 457
Cited by
Sorted by citations
Items 301–396 of 396
Mo, J., Kang, M., Ye, J.-X., Chen, J., Zhang, H., & Qing, C. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3051-5 · Cited by 9
Sharma, A., Cipriano, M. J., Ferrins, L., Hajduk, S. L., & Mensa‐Wilmot, K. (2022) · iScience · doi:10.1016/j.isci.2022.105302 · Cited by 9
Salih, S. M. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.01.128 · Cited by 9
Guyett, P. J., Behera, R., Ogata, Y., Pollastri, M. P., & Mensa‐Wilmot, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01865-16 · Cited by 9
Shen, T., Kuang, Y., Ashby, C. R., Lei, Y., Chen, A., Zhou, Y., Chen, X. '., Tiwari, A. K., Hopper-Borge, E. A., Ouyang, J., et al. (2009) · PLoS ONE · doi:10.1371/annotation/e57b4610-9029-48db-9d57-5cc0fa35b8ac · Cited by 9
Self-citationPlasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma
Marı́n, J. J. G., Macı́as, R. I. R., Cives-Losada, C., Peleteiro‐Vigil, A., Herráez, E., & Lozano, E. (2020) · Cells · doi:10.3390/cells9020498 · Cited by 8
Krchniaková, M., Paukovčeková, S., Chlapek, P., Neradil, J., Skoda, J., & Veselská, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.976955 · Cited by 8
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Salkeni, M. A., Rizvi, W., Hein, K. Z., & Higa, G. M. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s288344 · Cited by 9
ATP-Binding Cassette Subfamily G Member 2 in Acute Myeloid Leukemia: A New Molecular Target?
Damiani, D., & Tiribelli, M. (2024) · Biomedicines · doi:10.3390/biomedicines12010111 · Cited by 8
Liu, T., Peng, Y., Li, X., Liu, L., Liu, F., & He, L. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.003 · Cited by 8
Lin, B.-H., Li, Y.-C., Murakami, M., Wu, Y., Huang, Y.-H., Hung, T., Ambudkar, S. V., & Wu, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117542 · Cited by 7
Self-citationVispute, S. G., Chen, J.-J., Sun, Y.-L., Sodani, K. S., Singh, S., Pan, Y., Talele, T. T., Ashby, C. R., & Chen, Z. (2013) · Journal of cancer research updates · doi:10.6000/1929-2279.2013.02.04.9 · Cited by 7
Self-citationTo, K. K. W., Poon, D. C., Chen, X. G., & Fu, L. (2013) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-2-13 · Cited by 7
Self-citationKathawala, R. J., Li, T., Yang, D., Guo, H., Yang, D., Chen, X., Cheng, C., & Chen, Z. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25908 · Cited by 7
Self-citationWu, C., Hsieh, Y., Tseng, H.-Y., Huang, Y.-H., Li, Y., Hung, T., Wang, S.-P., & Wu, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113663 · Cited by 8
Self-citationWu, C., Lusvarghi, S., Tseng, P.-J., Hsiao, S.-H., Huang, Y.-H., Hung, T., & Ambudkar, S. V. (2020) · PubMed Central · Cited by 7
Self-citationMembrane drug transporters in cancer: From chemoresistance mechanism to therapeutic strategies
Pan, C., & Lee, L. T. O. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189272 · Cited by 7
Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930
Patel, J. P., Kuang, Y., Chen, Z., & Korlipara, V. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.070 · Cited by 6
Self-citationSmall Molecule Tyrosine Kinase Inhibitors: The New Dawn for Cancer Therapy
Noolvi, M. N., & Patel, H. (2011) · Letters in Drug Design & Discovery · doi:10.2174/157018012798192892 · Cited by 6
An, G., & Morris, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816434-1.00003-6 · Cited by 6
Jing, W., Zhang, X., Chen, R., Ye, X., Zhou, M., Li, W., Yan, W., Xuyun, X., & Peng, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.12172 · Cited by 6
Jing, W., Zhou, M., Chen, R., Ye, X., Li, W., Su, X., Luo, J., Wang, Z., & Peng, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7915 · Cited by 6
Self-citationRivkin, S. E., Muller, C. Y., Malmgren, J. A., Moon, J., Iriarte, D., Arthur, J., & Gerould, H. (2009) · Clinical Ovarian Cancer · doi:10.3816/coc.2009.n.018 · Cited by 6
Wu, C., Murakami, M., Li, Y.-C., Huang, Y.-H., Chang, Y., Hung, T., Wu, Y., & Ambudkar, S. V. (2023) · Pharmaceuticals · doi:10.3390/ph16111595 · Cited by 5
Self-citationQi, L., Zhang, B., Zhang, S., Ci, X., Wu, Q., Ma, G., Luo, A., Fu, L., King, J. L., Nahta, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16425 · Cited by 5
Self-citationAzuma, T. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1434 · Cited by 5
Overcoming ABCG2-mediated multidrug resistance by a mineralized hyaluronan–drug nanocomplex
Chen, W., Wang, F., Zhang, X., Hu, J., Wang, X., Yang, K., Huang, L., Xu, M., Li, Q., & Fu, L. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01545j · Cited by 5
Self-citationHow Physiologic Targets Can Be Distinguished from Drug-Binding Proteins
Mensa‐Wilmot, K. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.120.000186 · Cited by 6
Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs
Li, J., Ma, Z., Jiang, R., & Wu, B. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.802771 · Cited by 5
Development and application of novel analytical methods for molecularly targeted cancer therapeutics
Roche, S. (2011) · Dublin City University Open Access Institutional Repository (Dublin City University) · Cited by 5
Li, C., Zhang, B., Guo, J., Hu, F., Nie, W., Zheng, X., Wang, L., Lou, Y., Shen, Y., Han, B., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00659-z · Cited by 5
Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib
Xie, Z., Lv, J., Huang, W., Wu, Z., Zhu, R., Deng, Z., & Long, F. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115466 · Cited by 4
Li, C., Zhang, B., Guo, J., Hu, F., Nie, W., Zheng, X., Wang, L., Lou, Y., Shen, Y., Han, B., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00649-1 · Cited by 4
Guérin, M., Qian, C., Zhong, Q., Cui, Q., Guo, Y., Bei, J., Shao, J., Zhu, X., Huang, W., Wu, J., et al. (2012) · Science China Life Sciences · doi:10.1007/s11427-012-4398-4 · Cited by 4
Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.
Jaques, R., Xu, S., & Matsakas, A. (2020) · PubMed · doi:10.14670/hh-18-221 · Cited by 4
Clinically-weighted transcriptomic signatures for protein kinase inhibitor associated cardiotoxicityPreprint
van Hasselt, J. G. C., Hansen, J., Xiong, Y., Shim, J., Pickard, A., Jayaraman, G., Hu, B., Mahajan, M. C., Gallo, J., Sobie, E. A., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/075754 · Cited by 4
Liu, M., Zou, L., Zhang, N., Zhou, W., Pan, X., Deng, Y., Yue, Y., Wu, J., Liang, X., Chen, M., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02137-z · Cited by 3
Drug–drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors
Stromatt, J. C., Chowdhury, A. T., Huang, K. M., Hu, S., Sparreboom, A., Baker, S. D., & Eisenmann, E. D. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2606258 · Cited by 3
Kumbham, S., Rahman, K. M. M., Bosmajian, C., Bist, G., Foster, B. A., Woo, S., & You, Y. (2024) · Photochemistry and Photobiology · doi:10.1111/php.13982 · Cited by 3
Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer
Zhao, P., Li, F., & Huang, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819937-4.00010-8 · Cited by 3
Self-citationThe Role of ABC Multidrug Transporters in Resistance to Targeted Anticancer Kinase Inhibitors
Hegedüs, C., Hegedűs, T., & Sarkadi, B. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-09801-2_9 · Cited by 3
Shukla, S., Patel, A. S., & Ambudkar, S. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-23476-2_10 · Cited by 3
Self-citationResistance to HER2-Targeted Therapy
Theile, D., Lenz, G., Momand, J. A., & Kane, S. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_2 · Cited by 3
Simotinib as a modulator of P-glycoprotein
Huang, L., Shen, C., Chen, Y., Yan, H., Cheng, Z., & Zhu, Q. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000332 · Cited by 3
Ruginsk, B. E., Zattoni, I. F., Oliveira, A. H., Zanzarini, I. D. S., Rego, F. G. D. M., Picheth, G., Poso, A., Kronenberger, T., Goda, K., Moure, V. R., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118077 · Cited by 2
Rahman, I., Meda, A., Moore, K. A., Srivastava, P., Dasgupta, A., Sajid, A., Ambudkar, S. V., & Huang, H. (2025) · Photochemistry and Photobiology · doi:10.1111/php.70049 · Cited by 2
Self-citationSuleiman, A. A., Quagliariello, V., Spadafora, L., Russo, F. Y., & Maurea, N. (2026) · Pharmaceuticals · doi:10.3390/ph19060833 · Cited by 2
The Role of PDE-5 Inhibitors in Prostate Cancer
Das, A., Fadi, N., & Rakesh, C. (2011) · InTech eBooks · doi:10.5772/25380 · Cited by 2
Patel, A. S., Wang, D., Sim, H., Ambudkar, S. V., & Chen, Z. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-09801-2_8 · Cited by 2
Self-citationWang, F., Liang, Y.-J., Wu, X.-P., Su, X., & Fu, L. (2012) · 癌症：英文版 · doi:10.5732/cjc.011.10310 · Cited by 2
Self-citationZhao, H., Wei, H., & Wang, X. (2013) · Journal of cancer research updates · doi:10.6000/1929-2279.2013.02.01.8 · Cited by 2
Li, Y., Murakami, M., Huang, Y.-H., Hung, T., Wang, S.-P., Wu, Y., Ambudkar, S. V., & Wu, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112763 · Cited by 2
Self-citationBruton's Tyrosine Kinase (BTK) Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Zhang, H., & Qiu, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00008-0 · Cited by 2
Egido, E. (2014) · Buleria (Universidad de León) · doi:10.18002/10612/3608 · Cited by 2
Chandratre, S., Olsen, J., & Chen, B. (2025) · Photochemistry and Photobiology · doi:10.1111/php.14077 · Cited by 1
Insights and perspectives into the etiology of TKI-induced cardiotoxicity
Xu, V., Ahmed, B., Boleslav, B., Mager, D., Sparreboom, A., Sprowl, J. A., & Huang, K. M. (2026) · ASPET Discovery · doi:10.1016/j.aspetd.2026.100025 · Cited by 1
Ying‐ying, X., Yang, X.-Y., Chen, F., Yang, H., Zhang, C., Yan, J.-Z., Wu, S.-S., & Wang, L. (2026) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.70333 · Cited by 1
Hsiao, S.-H., Luo, S.-Y., Su, C.-Y., Tuo, W.-C., Chiang, C.-T., Li, Y., Huang, Y.-H., & Wu, C. (2014) · Journal of cancer research updates · doi:10.6000/1929-2279.2014.03.02.5 · Cited by 1
Self-citationGrowth Factor Signaling Pathways and Targeted Therapy
Swanson, K. D., Charest, A., Pollack, I. F., & Wong, E. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00021-8 · Cited by 1
Pranav, G., Yunali, V. A., Teng, Q., Zining, L., Bryan, C., Sandra, E. R., John, N., & Zhe-Sheng, C. (2019) · Journal of Molecular and Clinical Medicine · doi:10.31083/j.jmcm.2019.03.0301 · Cited by 1
Liang, S., Wang, F., Luo, M., Zhang, H., Wu, S.-C., Chen, Z., & Fu, L. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.10.014 · Cited by 1
Self-citationOgale, P., Nikam, V. S., Gautam, M., Gairola, S., & Jadhav, S. S. (2020) · Springer eBooks · doi:10.1007/978-981-15-9038-2_3 · Cited by 1
Characterisation and modulation of drug resistance in lung cancer cell lines
Dunne, G. (2010) · Dublin City University Open Access Institutional Repository (Dublin City University) · Cited by 1
Aird, K. M. (2010) · DukeSpace (Duke University) · Cited by 1
Aekrungrueangkit, C., Wangngae, S., Kamkaew, A., Ardkhean, R., Boonsombat, J., Ruchirawat, S., & Khotavivattana, T. (2022) · Research Square · doi:10.21203/rs.3.rs-1689180/v1 · Cited by 1
Pharmacological modulation and manipulation of cancer drug resistance
Devery, A. (2010) · Arrow@dit (Dublin Institute of Technology) · Cited by 1
Mo, W. (2012) · IUScholarWorks (Indiana University) · doi:10.7912/c2/293
Bhosle, J. (2012) · UCL Discovery (University College London)
Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib
van Erp, P. E. J., & Hubertha, P. (2009)
Improving delivery of molecularly targeted agents to glioma
Agarwal, S. (2011) · University of Minnesota Digital Conservancy (University of Minnesota)
Yashiro, M., Qiu, H., Hasegawa, T., Zhang, X., Morisaki, T., Fukuoka, T., Aomatsu, N., Hirakawa, T., Sakurai, K., Kubo, N., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-780
Zhao, X., Xie, J., Chen, X., Sim, H. M., Zhang, X., Liang, Y.-J., Singh, S., Talele, T. T., Sun, Y.-L., Ambudkar, S. V., et al. (2012)
Self-citationCuello-Carrión, F. D., Fanelli, M. A., Castro, G. N., Cayado-Gutiérrez, N., & Ciocca, D. R. (2015) · Current Cancer Therapy Reviews · doi:10.2174/1573394712666151215213709
Regulska, K., Stanisz, B. J., & Gieremek, P. (2014)
Regulating SQSTM1/P62 and Wnt/β-catenin signaling of EMT to constrain TNBC invasiveness.Preprint
Shome, R., Sen, P., & Ghosh, S. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1630401/v1
Benzene fused pyrimidine-based derivatives and their biological properties
Kelm, J. M., Aruri, H., Nyalapatla, P. R., & Gavande, N. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18616-5.00005-3
Mi, Y., Liang, Y.-J., Huang, H., Zhao, H., Wu, C., Wang, F., Tao, L.-Y., Zhang, C.-Z., Dai, C., Tiwari, A. K., et al. (2023) · doi:10.1158/0008-5472.c.6500690
Self-citationRayapolu, R. G., Patil, H. R., Arawindh, R., Apte, S., & Venuganti, V. V. K. (2025) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2025.2595559
Additional file 2 of Reversal of ABCB1-related multidrug resistance by ERK5-IN-1
Wang, F., Li, D., Zheng, Z., Kin Wah To, K., Chen, Z., Zhong, M., Su, X., Chen, L., & Fu, L. (2020) · Figshare · doi:10.6084/m9.figshare.11978976
Self-citationWu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Growth factor signaling pathways and targeted therapy
Aulakh, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00061-9
Zalpoor, H., Teow, J. Y., Ferdousmakan, S., Golestani, N., Nabi‐Afjadi, M., & Ramasamy, T. S. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02853-9
Zhang, H., Li, X., Xie, B., Wu, F., Ren, J., Wang, J., Wang, L., Wen, T., Kang, J., & Qian, Y. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2714456
BindingDB (2022) · UC San Diego · doi:10.7270/q2v4101k
BindingDB Entry 50034090: Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930.
BindingDB (2012) · UC San Diego · doi:10.7270/q2445mw7
Metadata
- Authors
- Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., Chen, L.-M., Shi, C.-J., Ambudkar, S. V., Chen, Z.-S., & Fu, L.-W.
- Affiliations
- Sun Yat-sen University (CN)
- St. John's University (US)
- National Institutes of Health (US)
- 1State Key Laboratory for Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou, China;
- ORCID
- Venue
- Cancer Research
- Published
- 2008-09-30
- Volume
- 68
- Issue
- 19
- Pages
- 7905-7914
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC2652245
- OpenAlex
- W2098064809
- Cited by
- 386
- References
- 54
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 22 · 2021: 17 · 2020: 32 · 2019: 26 · 2018: 20 · 2017: 23 · 2016: 22 · 2015: 26 · 2014: 43 · 2013: 16 · 2012: 38
- FWCI
- 11.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- St. John's University (579-1110)
- Sun Yat-sen University
- National Institutes of Health
- National Cancer Institute (Z01BC010030, Z01BC010622)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- lapatinib, multidrug resistance reversal, P-glycoprotein, ABCG2, ABC transporters, drug efflux, doxorubicin accumulation, methotrexate transport, paclitaxel, tyrosine kinase inhibitors, combination chemotherapy
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Lapatinib, Adenosine Triphosphatases, Animals, Antineoplastic Combined Chemotherapy Protocols, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Mice, Nude, Neoplasm Proteins, Neoplasms, Quinazolines, Transfection, Up-Regulation, Gene Expression Regulation, Neoplastic, Paclitaxel, Drug Resistance, Multiple, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Xenograft Model Antitumor Assays, Tumor Burden, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
